Full name
A Phase 3, 52-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study With Open-Label Extension of BLU-5937 (Camlipixant) in Adult Participants With Refractory Chronic Cough, Including Unexplained Chronic Cough
NCT Number
NCT05599191
Geography
US
Non-US
Locations
Argentina, Belgium, Canada, Colombia, France, Hungary, India, Israel, Netherlands, Poland, South Africa, Spain, Turkey, United Kingdom, United States
Primary Endpoints
24-Hour Cough Frequency. Week 12
External Link
https://clinicaltrials.gov/study/NCT05599191
Order
1
Disease
Version
Phase
3